REGULATORY

MHLW Panel Sets Safety Rules for Upcoming Pomalyst Generics

By Sakura Kono February 2, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s Ministry of Health, Labor and Welfare (MHLW) has revealed that multiple companies, including Fujimoto Pharmaceutical, have filed approval applications for generic versions of the blood cancer drug Pomalyst (pomalidomide). At a meeting of its safety management panel for thalidomide-related…

To read the full story

REGULATORY

MHLW Set to Launch Searchable Drug Supply Database in April
February 3, 2026
MHLW Pushes Back GCP Ordinance Revision to Summer
February 3, 2026
Public Comments Warn Japan’s Drug Pricing System Cannot Reflect Inflation: Chuikyo
February 2, 2026
Chuikyo Agrees to Apply Originator Optimal-Use Guidelines to Biosimilars
February 2, 2026
MHLW Panel Sets Safety Rules for Upcoming Pomalyst Generics
February 2, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

TSE’s Growth Market Reform Puts Pressure on Biotechs

By Tatsuya Otsuka

Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…